13.02.2018 23:16:40
|
Merck Discontinues APECS Study On Verubecestat Following EDMC Recommendation
(RTTNews) - Merck (MRK) announced that it will be stopping protocol 019, also known as the APECS study, following a recommendation by the external Data Monitoring Committee (eDMC), that it was unlikely that positive benefit/risk could be established if the trial continued.
The Phase 3 study evaluated verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with prodromal Alzheimer's disease (AD).
The company plans to present the data from the APECS study at an upcoming medical meeting.
Roger Perlmutter, president, Merck Research Laboratories, stated, "We are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer's disease,"

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
21.03.25 |
Schwacher Wochentag in New York: Dow Jones liegt am Freitagnachmittag im Minus (finanzen.at) | |
21.03.25 |
NYSE-Handel Dow Jones am Mittag ohne Schwung (finanzen.at) | |
19.03.25 |
NYSE-Handel: Börsianer lassen Dow Jones schlussendlich steigen (finanzen.at) | |
18.03.25 |
Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor einem Jahr eingebracht (finanzen.at) | |
14.03.25 |
NYSE-Handel: Börsianer lassen Dow Jones steigen (finanzen.at) | |
14.03.25 |
Freundlicher Handel: Dow Jones zum Start des Freitagshandels auf grünem Terrain (finanzen.at) | |
13.03.25 |
Minuszeichen in New York: Dow Jones zum Handelsende schwächer (finanzen.at) | |
13.03.25 |
Schwacher Handel: Dow Jones am Donnerstagnachmittag in Rot (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 87,30 | 0,58% |
|